malignancy
Conditions
Interventions
The DNA nanocarrier containing Siglec-15 aptamer group:None
Carimycin experimental tumor group:None
control group:None
The DNA nanocarrier containing Siglec-15 aptamer loaded with camycin group:None
Sponsors
Ningbo Medical Centre Lihuili Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients are between 18 and 75 years old. Clinically diagnosed with a tumor.
Exclusion criteria
Exclusion criteria: 1. Severe mental illness that is not under control; 2. Other diseases requiring long-term use of high doses of glucocorticoids or other immunosuppressants; 3. Allergy to macrolide antibiotics; 4. Known acute or chronic active HBV or HCV infection requiring non-nucleoside antiviral treatment; 5. Pregnant patients; 6. Use of other macrolide antibiotics within 3 days prior to enrollment; 7. Any medical condition, treatment, or abnormal laboratory history, or existing evidence that the investigator believes may confound the study results or interfere with the participant's ability to complete the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor organoid viability; | — |
Countries
China
Contacts
Public ContactFei Guo
Ningbo Medical Centre Lihuili Hospital
Outcome results
None listed